Accessibility Menu
Caris Life Sciences logo

Caris Life Sciences(NASDAQ) CAI

Market Cap$5.65BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-41%
5 YearN/A
1 Year-31%
1 Month+14%
$20.01
+21.64%
+3.56Today
After hours$19.97-$0.04 (-0.20%)
Caris Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 20.002026-08-06
Caris Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+24.3%USD 16.092026-07-30
1 month+14.48%USD 17.472026-07-07
3 month+23.84%USD 16.152026-05-08
Year to date-25.87%USD 26.982025-12-31
1 year-30.92%USD 28.952025-08-06
Since inception-41.25%USD 28.002025-06-18

Caris Life Sciences Financials at a Glance

Market Cap

$5.65BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$989.61M

Net Income (TTM)

$105.14M

EPS (TTM)

$0.37

P/E Ratio

53.72

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$20.01

Volume

11,272,923.9

Open

$19.00

Previous Close

$20.00

Daily Range

$17.95 - $20.11

52-Week Range

$14.19 - $42.50

Estimated Earnings Date

Nov 4, 2026

CAI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Caris Life Sciences

Caris helps doctors find the best treatments for cancer patients.

It uses computers and biology to study a person's unique health information.

This helps drug companies create better medicines for serious diseases.

Tools for Targeted Treatment

  • Molecular Profiling Services: Tests using tissue and blood samples to help doctors choose cancer treatments; accounts for 98% of revenue.
  • Pharma R&D Services: Data and research tools provided to drug companies to develop new medicines; makes up 2% of revenue.
  • MI Profile: A service that analyzes cancer tissue to identify specific genetic changes.
  • Caris Assure: A blood-based test that monitors cancer and tracks how patients respond to treatment.

Steps Toward Scaling

  • Launched the MI Cancer Seek solution in January 2025 as a companion diagnostic for tissue profiling.
  • Expanded the commercial use of Caris Assure in 2024 to provide blood-based therapy selection.
  • Partnered with major drug companies like Moderna, AbbVie, and Genentech to support research projects.
  • Completed an initial public offering on the Nasdaq Stock Market in June 2025.
  • Secured a new financing agreement in April 2026 for up to $1.2 billion in credit facilities.

What Makes Caris Different

Caris manages one of the largest cancer datasets with over 1,070,000 cases analyzed by March 31, 2026. The company uses high-performance computing and machine learning to turn biological samples into medical insights.

The Quarterly Scorecard

  • Total revenue reached $216 million in Q1 2026, up 79% from Q1 2025.
  • Operating income turned positive at $5 million in Q1 2026, improved from a $58 million loss in Q1 2025.
  • Net loss narrowed to $510,000 in Q1 2026, improved from a $103 million loss in Q1 2025.
  • Free cash flow turned positive at $22.5 million in Q1 2026, up from a $34 million outflow in Q1 2025.

Evolution of Precision Care

Caris has transitioned from a private research firm to a public technology-driven biology company. Its shift toward positive cash flow and large-scale data analysis supports its role in modern cancer care.

AI Generated • May 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,846

CEO

David Dean Halbert

Website

www.carislifesciences.com

Headquarters

Irving, TX 75039, US

CAI Financials

Key Financial Metrics (TTM)

Gross Margin

69.66%

Operating Margin

15.49%

Net Income Margin

10.62%

Return on Equity

18.77%

Return on Capital

4.72%

Return on Assets

8.55%

Earnings Yield

1.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.65BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

282.68M

Volume

11.27M

Avg. Volume

3.60M

Financials (TTM)

Gross Profit

$689.36M

Operating Income

$153.26M

EBITDA

$166.15M

Operating Cash Flow

$201.43M

Capital Expenditure

-$54.94M

Free Cash Flow

$146.49M

Cash & ST Invst.

$793.12M

Total Debt

$452.40M

Caris Life Sciences Performance Analysis

Caris Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 306,128,000N/A
20242024-12-31USD 412,260,00034.7%
20252025-12-31USD 812,033,00097.0%
Caris Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3019.5%
Q42025-12-3135.1%
Q12026-03-31-26.2%
Q22026-06-3022.0%
Caris Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -1.65N/A
20242024-12-31USD -1.35-18.2%
20252025-12-31USD -1.9041.5%
Caris Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30104.4%
Q42025-12-31241.5%
Q12026-03-31-100.6%
Q22026-06-30-27.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$263.71M

+45.4%

Gross Profit

$179.60M

+58.0%

Gross Margin

68.10%

N/A

Market Cap

$5.65BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.06M

N/A

Employees

1,846

N/A

Net Income

-$637.00K

+99.1%

EBITDA

$8.61M

+118.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$793.12M

+10.0%

Total Debt

$452.40M

+8.0%

Accounts Receivable

$116.89M

+129.7%

Inventory

$123.79M

+204.8%

Long Term Debt

$445.86M

+8.3%

Short Term Debt

$6.55M

-11.4%

Return on Assets

8.55%

N/A

Return on Invested Capital

14.76%

N/A

Free Cash Flow

$28.94M

+390.3%

Operating Cash Flow

$61.35M

+741.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRUSMerus N.V.
$90.00+0.00%
RYTMRhythm Pharmaceuticals, Inc.
$112.10+1.26%
ABVXAbivax S.A.
$130.00+3.68%
CYTKCytokinetics, Incorporated
$81.37+3.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$114.92+0.06%
NVDANvidia
$218.99-0.00%
TTDThe Trade Desk
$17.67-0.07%
SOUNSoundHound AI
$7.08+0.10%

Questions About CAI

What is the current price of Caris Life Sciences?

Caris Life Sciences is trading at $20.00 per share.

What is the 52-week range for Caris Life Sciences?

Over the past 52 weeks, Caris Life Sciences has traded between $14.19 and $42.50.

How much debt does Caris Life Sciences have?

As of the most recent reporting period, Caris Life Sciences reported total debt of $452.40M.

How much cash does Caris Life Sciences have on hand?

Caris Life Sciences reported $690.92M in cash and cash equivalents in its most recent financial results.

What is Caris Life Sciences’s dividend yield?

Caris Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services